Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Chemotherapy].
Ikeda M, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Okusaka T. Ikeda M, et al. Among authors: mitsunaga s. Gan To Kagaku Ryoho. 2010 Mar;37(3):408-12. Gan To Kagaku Ryoho. 2010. PMID: 20332676 Review. Japanese.
Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma.
Kawashima M, Kohno R, Nakachi K, Nishio T, Mitsunaga S, Ikeda M, Konishi M, Takahashi S, Gotohda N, Arahira S, Zenda S, Ogino T, Kinoshita T. Kawashima M, et al. Among authors: mitsunaga s. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1479-86. doi: 10.1016/j.ijrobp.2009.12.048. Epub 2010 Jun 3. Int J Radiat Oncol Biol Phys. 2011. PMID: 20605350
Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S, Satake M, Arai Y. Iwasa S, et al. Among authors: mitsunaga s. Jpn J Clin Oncol. 2011 Jun;41(6):770-5. doi: 10.1093/jjco/hyr037. Epub 2011 Apr 1. Jpn J Clin Oncol. 2011. PMID: 21459893
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T. Morizane C, et al. Among authors: mitsunaga s. Cancer Chemother Pharmacol. 2012 Apr;69(4):957-64. doi: 10.1007/s00280-011-1786-6. Epub 2011 Nov 26. Cancer Chemother Pharmacol. 2012. PMID: 22120961 Clinical Trial.
210 results